KIT and neoplasm: In our case, the tumor was 10.5 cm in size with a mitotic rate of 4–5 mitosis/25 HPF, putting him in the high-risk category of Fletcher Classification, necessitating imatinib therapy (tyrosine kinase inhibitor targeting KIT) after surgery, which was started postoperatively and was planned to be continued for 3 years.